B-CELL LYMPHOPROLIFERATIVE DISORDER
Clinical trials for B-CELL LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new B-CELL LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for B-CELL LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug shows promise for rare blood cancer
Disease control Recruiting nowThis phase 2 trial is testing whether epcoritamab, a type of antibody, can help people with Waldenstrom Macroglobulinemia (a rare blood cancer) who have already received treatment. The study will enroll 20 participants and measure how many respond to the drug. Epcoritamab is give…
Matched conditions: B-CELL LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: Gottfried von Keudell, MD PhD • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for rare blood cancer: pacritinib trial opens for patients who need better options
Disease control Recruiting nowThis study tests whether the drug pacritinib is safe and effective for adults with Waldenström macroglobulinemia, a rare blood cancer, when previous treatments have stopped working. About 30 participants will receive pacritinib and be monitored for tumor shrinkage and side effect…
Matched conditions: B-CELL LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: Shayna Sarosiek, MD • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC